

PROVEXIS

- Provexis' lead product addresses a \$4bn market with a research-backed, natural ingredient that helps maintain a healthy heart and benefits circulation. The first product is a functional juice drink aimed at the preventative health market and is available nationally in major supermarkets and health food stores.

□ AT A GLANCE

- Established by ANGLE in 2000
- Listed on AIM during June 2005
- Flagship product, Sirco®, launched January 2006

□ CONTACT DETAILS

Provexis plc
20 Mortlake High Street
London
SW14 8JN

T: +44 (0)208 392 6631
F: +44 (0)208 392 6632
E: enquiries@provexis.com
www.provexis.com

□ ABOUT ANGLE

Founded in 1994, ANGLE is an international Consulting, Management and Ventures company focusing on the commercialisation of technology and the development of technology-based industry.

ANGLE Ventures founds, develops and operates its own technology-based businesses. Utilising our in-house Progeny® process, we commercialise intellectual property developed by technology partners in the academic, private and public sectors.

Almost half of all deaths in Europe are a result of circulatory disease, including cardiovascular disease, heart attack and stroke. As the finger of blame for the rise in such conditions points to poor diet, a \$4bn heart-health market hungers for natural solutions that counteract this trend.

Answering the call for natural products to help maintain health, ANGLE established Provexis in 2000 to develop and license a range of scientifically-tested products based on natural, bioactive ingredients.


Provexis develops scientifically-proven novel bioactive ingredients for integration into functional foods and beverages. Provexis' focuses on major health areas including cardiovascular health, cancer and Inflammatory Bowel Disease.

Provexis' flagship brand, Sirco® is a fruit juice drink that contains the natural bioactive, Fruitflow®, which helps the blood flow smoothly to maintain a healthy heart and circulation. Fruitflow has been shown in multiple human trials to reduce the aggregation, or 'clumping together' of blood platelets – to help ensure healthy, normal blood flow. Platelet aggregation is a cause of unwanted blood clots inside blood vessels. Sirco's health benefits are observable within just three hours of consumption.

CURRENT ACTIVITIES AND OPPORTUNITIES

Sirco® has successfully completed clinical human trials and is now the UK's principal commercialisation vehicle for the active ingredient.

While in joint venture partnership with Nutrinovator Holdings plc, Provexis completed the product development of Sirco® including taste and texture refinement. It also established manufacturing and distribution arrangements and finalised packaging and branding.





Sirco® helps blood flow smoothly to maintain a healthy heart – its health benefits are observable within three hours of consumption.

Provoxis' dedication to gaining clinical evidence to back its health benefit claims stands it in excellent stead ahead of other market offerings.

In the meantime, further products are in the pipeline. These include a plantain extract which will underpin a novel medical food for the dietary management of Inflammatory Bowel Disease and a beverage containing a proprietary vegetable extract known to reduce the risk of specific cancers.

June 2005 saw Provoxis complete its reverse acquisition of Nutrinovator Holdings plc, secure additional financial investment and make its debut on AIM. Provoxis launched Sirco® in January 2006 and is available nationally in major supermarkets and health food stores.

□ PROVEXIS AND ANGLE

Provoxis constitutes a further major application of ANGLE's Progeny® process which is designed to commercialise intellectual property. ANGLE itself is a category pioneer, leader and expert in technology wealth creation (TWC). Spanning the worlds of technology, finance and management, it applies this core expertise in three ways to:

- Enable companies to participate effectively in TWC (Management Services);
- Help firms decide how to optimise and progress the value of their engagement in TWC (Consulting); and finally, as with Provoxis, to
- Deliver direct results from TWC (Ventures).

ANGLE retains a 25% share in Provoxis, which is now a publicly listed company in its own right under the symbol PXS



□ PROVEXIS MANAGEMENT TEAM

Dr Stephen Franklin, BSc PhD MBA
CEO

Steve has over 15 years entrepreneurial experience in the creation and development of bioscience companies, and has been CEO of Provoxis since September 2002. Prior to this, he was a Principal Executive with ANGLE plc.

Stephen Moon, MBA
Commercial Director

Stephen has over 20 years senior cross-functional experience in the grocery brands industry. Stephen was formerly the Strategy Planning and Worldwide Business Development Director for GlaxoSmithKline's Nutritional Healthcare business before founding Nutrinovator in 2002.

Fiona Vigar, BA (Hons) MCIM
Director of Marketing

Fiona has over 15 years sales and marketing experience with Diageo and GlaxoSmithKline. She was formerly Marketing Category Director for GlaxoSmithKline's Lucozade and Lucozade Sport brands in the UK, responsible for revenue growth of 70%, before becoming a founding director of Nutrinovator.

Ian Houghton
Director of Sales

Ian has over 20 years experience in the beverage industry with Britvic, Quaker and Ubevco. As Sales Director of Ubevco he was responsible for building a salesforce of 75 which contributed to the growth of Red Bull's UK sales from £3m to over £130m.

Dr Niamh O'Kennedy, BSc MSc PhD
Principal Scientist

Niamh is a research chemist, specialising in the field of natural products chemistry. Her experience in isolating and characterising plant-derived compounds and understanding the roles these play in complex biological systems has been pivotal in the development of Provoxis' product portfolio.